ORG IMS has plans to expand its existing business outreach by introducing two new products shortly. The company will launch its special analysis studies on oncology and vaccine segments by the end of 2008.
Speaking to Pharmabiz, Shailesh Gadre, managing director, ORG IMS Research, said, "Currently, we are offering services of information and analysis to over 150 clients and consulting business to over 25 clients. As Indian pharmaceutical industry has lots of growth potential compared to developed countries, several clients have requested us to provide solutions for the oncology and vaccine segment. Currently, we are studying the potential for those areas and we are expecting to launch these two new services by the end of current year".
Today the MNCs are caught in the middle of products going off patent and a weak product pipeline. Given the escalating R&D costs, many companies are likely to use Indian facilities for the R&D work. However, most global research is focussing around speciality care whereas developing countries would also struggle with primary care diseases for time to come. Commenting on this, Gadre, said, "Still there are several diseases like dengue, malaria, typhoid and tuberculosis in the developing as well as developed countries. There is lot of scope for the research in these diseases. Government should give subsidies for undertaking research in these fields".
ORG IMS analyses the pharmaceutical market performance, identify the growth opportunities and strives towards being one stop shop for providing evidence based solution for healthcare companies.